A Phase 2 interventional study of LDV/SOF and SOF in Chronic Hepatitis C, sponsored by Gilead Sciences. Completed at 2 sites in New Zealand. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-11-16.
Sponsored by Gilead Sciences · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 50 studies testing sofosbuvir in Hepatitis C, Chronic — none open to participants now, 1 under way, none of them phase 3. Sofosbuvir · Hepatitis C, Chronic.
Among the 50 studies testing sofosbuvir in Hepatitis C, Chronic, this one is the 5th largest by enrollment, is one of 5 that started in 2013, is one of 15 in phase 2, and was the 12th registered.
950 studies on the registry are indexed under Hepatitis C, Chronic; 8 are open to participants now.
Browse Hepatitis C, Chronic studies →None of the 50 studies testing sofosbuvir in Hepatitis C, Chronic is open now. The open studies under Hepatitis C, Chronic, anywhere →
Sofosbuvir: first FDA approval 2013 (SOVALDI), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 5 Hepatitis C, Chronic studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
50 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 19 · Phase 3 14 · Phase 4 13
First in 2011; this study’s year is marked. 5 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 359 is above the median of 90 across 696 interventional studies indexed under Hepatitis C, Chronic.
Median enrollment 65 across the 50 interventional studies. Of the 40 that completed or were terminated, 22 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 50 have an industry lead sponsor. The 10 most frequent:
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
34 studies in Hepatitis C, Chronic by Gilead Sciences: none open now, none under way, none of them phase 3. Of 33 finished, 21 (64%) have results posted.
Among the 34 studies in Hepatitis C, Chronic by Gilead Sciences, this one is the 5th largest by enrollment of the 31 interventional ones that give a count, is one of 7 that started in 2013, is one of 16 in phase 2, and was the 26th registered.
Gilead Sciences’s Hepatitis C, Chronic studies by the year they started, since 2010.
None of the studies under way reaches primary completion within a year.
Among the 50 studies testing sofosbuvir in Hepatitis C, Chronic, from their registry updates:
Among Gilead Sciences’s 34 in Hepatitis C, Chronic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the antiviral efficacy, safety, tolerability of combination therapy with sofosbuvir (SOF) containing regimens for the treatment of chronic hepatitis C virus (HCV) infection.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LDV/SOF + RBV for 12 weeks in participants with genotype 1 HCV infection and who failed to achieve sustained virologic response (SVR) in a previous Gilead sofosbuvir study
Drug: LDV/SOF · Drug: RBV
SOF + PEG + RBV for 12 weeks in participants with genotype 2 or 3 HCV infection and who failed to achieve SVR in a previous Gilead sofosbuvir study
Drug: SOF · Drug: RBV · Drug: Peg-IFN
LDV/SOF+RBV for 12 weeks in treatment-experienced participants with genotype 1 HCV infection and advanced liver fibrosis or compensated liver fibrosis
Drug: LDV/SOF · Drug: RBV
LDV/SOF + GS-9669 for 12 weeks in treatment-experienced participants with genotype 1 HCV infection and advanced liver fibrosis or compensated liver fibrosis
Drug: LDV/SOF · Drug: GS-9669
LDV/SOF for 12 weeks in treatment-naive participants with genotype 3 HCV infection
Drug: LDV/SOF
LDV/SOF + RBV for 12 weeks in treatment-naive participants with genotype 3 HCV infection
Drug: LDV/SOF · Drug: RBV
LDV/SOF for 12 weeks in treatment-naive or treatment-experienced participants with genotype 6 HCV infection
Drug: LDV/SOF
LDV/SOF + RBV for 12 weeks in treatment-experienced participants with genotype 3 HCV infection
Drug: LDV/SOF · Drug: RBV
LDV/SOF for 12 weeks in participants with genotype 1 HCV infection and Child-Pugh Turcotte (CPT) B cirrhosis
Drug: LDV/SOF
SOF+VEL (25 mg) for 8 weeks in treatment-naive noncirrhotic participants with genotype 3 HCV infection
Drug: SOF · Drug: VEL
SOF+VEL(25 mg)+RBV for 8 weeks in treatment-naive noncirrhotic participants with genotype 3 HCV infection
Drug: SOF · Drug: RBV · Drug: VEL
SOF+VEL (100 mg) for 8 weeks in treatment-naive noncirrhotic participants with genotype 3 HCV infection
Drug: SOF · Drug: VEL
SOF+VEL (100 mg)+RBV for 8 weeks in treatment-naive noncirrhotic participants with genotype 3 HCV infection
Drug: SOF · Drug: RBV · Drug: VEL
LDV/SOF+RBV for 24 weeks in participants with genotype 1, 2, 3, or 6 HCV infection and who failed to achieve SVR in a previous Gilead sofosbuvir study
Drug: LDV/SOF · Drug: RBV
LDV/SOF for 12 weeks in participants with genotype 1 HCV and hepatitis B virus (HBV) coinfection
Drug: LDV/SOF
Ledipasvir/sofosbuvir (LDV/SOF) (90 /400 mg) fixed-dose combination (FDC) tablet administered orally once daily
Also known as: Harvoni®, GS-5885/GS-7977
SOF 400 mg tablet administered orally once daily
Also known as: GS-7977, Sovaldi®
Ribavirin (RBV) 200 mg tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
pegylated interferon (Peg-IFN) 180 µg administered subcutaneously once weekly
Also known as: Pegasys®
GS-9669 500 mg (2 × 250 mg tablet) administered orally once daily
Velpatasvir (VEL) tablet(s) administered orally once daily
Also known as: GS-5816
Percentage of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12)
SVR12 is defined as HCV RNA \< lower limit of quantification (LLOQ) at 12 weeks after stopping study treatment.
Time frame: Posttreatment Week 12
Percentage of Participants With Adverse Events Leading to Permanent Discontinuation of Study Drug(s)
Time frame: Up to 24 weeks plus 30 days
Percentage of Participants With HCV RNA < LLOQ (15 IU/mL) While on Treatment
Time frame: Weeks 1 and 2
Percentage of Participants With HCV RNA < LLOQ (15 IU/mL) While on Treatment
Time frame: Weeks 4, 6, and 8
Percentage of Participants With HCV RNA < LLOQ (15 IU/mL) While on Treatment
Time frame: Week 10
Percentage of Participants With HCV RNA < LLOQ (15 IU/mL) While on Treatment
Time frame: Week 12
Percentage of Participants With HCV RNA < LLOQ (15 IU/mL) While on Treatment
Time frame: Weeks 16, 20, and 24
Percentage of Participants With HCV RNA < LLOQ (15 IU/mL) at 2, 4, 8, and 24 Weeks After Discontinuation of Therapy (SVR2, SVR4, SVR8, and SVR 24)
Time frame: Posttreatment Weeks 2, 4, 8, and 24
For Cohort 6, Percentage of Participants With HCV RNA < LLOQ (15 IU/mL) at 16 and 20 Weeks After Discontinuation of Therapy (SVR16 and SVR 20)
Time frame: Posttreatment Weeks 16 and 20
Percentage of Participants With On-treatment Virologic Failure
On-treatment virologic failure was defined as: * Breakthrough (confirmed HCV RNA ≥ LLOQ after having previously had HCV RNA \< LLOQ while on treatment), or * Rebound (confirmed \> 1 log10 IU/mL increase in HCV RNA from nadir while on treatment), or * Non-response (HCV RNA persistently ≥ LLOQ through 8 weeks of treatment)
Time frame: Up to Posttreatment Week 24
Percentage of Participants Experiencing Viral Relapse
Viral relapse is defined as HCV RNA ≥ LLOQ during the post-treatment period having achieved HCV RNA \< LLOQ at end of treatment, confirmed with 2 consecutive values or last available post-treatment measurement.
Time frame: Up to Posttreatment Week 24
Participants were enrolled at a total of 2 study sites in New Zealand. The first participant was screened on 3 April 2016. The last study visit occurred on 25 May 2015.
| Milestone | Cohort 1,Group 1: LDV/SOF+RBV 12 wk (GT1 SOF Retreatment) | Cohort 1,Group 2: SOF+Peg+RBV 12 wk (GT2,3 SOF Retreatment) | Cohort 2,Group 1: LDV/SOF+RBV 12 wk (GT 1 TE, Liver Disease) | Cohort 2,Group 2: LDV/SOF+GS-9669 12 wk (GT1 TE, Liver Disease | Cohort 2,Group 3: LDV/SOF 12 wk (GT3 TN) | Cohort 2,Group 4: LDV/SOF+RBV 12 wk (GT3 TN) | Cohort 2,Group 5: LDV/SOF 12 wk (GT6 TE/TN) | Cohort 2,Group 6: LDV/SOF+RBV 12 wk (GT3 TE) | Cohort 3,Group 1: LDV/SOF 12 wk (GT1 Cirrhotic CPT B) | Cohort 4,Group 1: SOF+VEL 25mg 8 wk (GT3 TN Noncirrhotic) | Cohort 4,Group 2: SOF+VEL 25mg+RBV 8 wk (GT3 TN Noncirrhotic) | Cohort 4,Group 3: SOF+VEL 100mg 8 wk (GT3 TN Noncirrhotic) | Cohort 4,Group 4: SOF+VEL 100mg+RBV 8 wk (GT3 TN Noncirrhotic) | Cohort 5,Group 1: LDV/SOF+RBV 24 wk (GT1/3 SOF Retreatment) | Cohort 6,Group 1: LDV/SOF 12 wk (GT1, HCV and HBV Coinfection) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 19 | 10 | 25 | 26 | 25 | 26 | 25 | 51 | 20 | 27 | 24 | 27 | 26 | 20 | 8 |
| Completed | 19 | 9 | 25 | 26 | 18 | 25 | 24 | 40 | 13 | 26 | 22 | 25 | 25 | 15 | 8 |
| Not completed | 0 | 1 | 0 | 0 | 7 | 1 | 1 | 11 | 7 | 1 | 2 | 2 | 1 | 5 | 0 |
| Withdrew: Lack of efficacy | 0 | 1 | 0 | 0 | 5 | 0 | 0 | 8 | 7 | 0 | 1 | 0 | 0 | 3 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 0 |
| Withdrew: Withdrew consent | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Upper g-i haemorrhage | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Enrolled/randomized but not treated | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
SVR12 is defined as HCV RNA \< lower limit of quantification (LLOQ) at 12 weeks after stopping study treatment.
| percentage of participants | Cohort 1,Group 1: LDV/SOF+RBV 12 wk (GT1 SOF Retreatment) | Cohort 1,Group 2: SOF+Peg+RBV 12 wk (GT2,3 SOF Retreatment) | Cohort 2,Group 1: LDV/SOF+RBV 12 wk (GT 1 TE, Liver Disease) | Cohort 2,Group 2: LDV/SOF+GS-9669 12 wk (GT1 TE, Liver Disease | Cohort 2,Group 3: LDV/SOF 12 wk (GT3 TN) | Cohort 2,Group 4: LDV/SOF+RBV 12 wk (GT3 TN) | Cohort 2,Group 5: LDV/SOF 12 wk (GT6 TE/TN) | Cohort 2,Group 6: LDV/SOF+RBV 12 wk (GT3 TE) | Cohort 3,Group 1: LDV/SOF 12 wk (GT1 Cirrhotic CPT B) | Cohort 4,Group 1: SOF+VEL 25mg 8 wk (GT3 TN Noncirrhotic) | Cohort 4,Group 2: SOF+VEL 25mg+RBV 8 wk (GT3 TN Noncirrhotic) | Cohort 4,Group 3: SOF+VEL 100mg 8 wk (GT3 TN Noncirrhotic) | Cohort 4,Group 4: SOF+VEL 100mg+RBV 8 wk (GT3 TN Noncirrhotic) | Cohort 5,Group 1: LDV/SOF+RBV 24 wk (GT1/3 SOF Retreatment) | Cohort 6,Group 1: LDV/SOF 12 wk (GT1, HCV and HBV Coinfection) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Percentage of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12) | 100 | 90 | 100 | 100 | 64.0 | 100 | 96.0 | 82.0 | 65.0 | 100 | 87.5 | 96.3 | 100.0 | 75 | 100 |
| Percentage of participants | Cohort 1,Group 1: LDV/SOF+RBV 12 wk (GT1 SOF Retreatment) | Cohort 1,Group 2: SOF+Peg+RBV 12 wk (GT2,3 SOF Retreatment) | Cohort 2,Group 1: LDV/SOF+RBV 12 wk (GT 1 TE, Liver Disease) | Cohort 2,Group 2: LDV/SOF+GS-9669 12 wk (GT1 TE, Liver Disease | Cohort 2,Group 3: LDV/SOF 12 wk (GT3 TN) | Cohort 2,Group 4: LDV/SOF+RBV 12 wk (GT3 TN) | Cohort 2,Group 5: LDV/SOF 12 wk (GT6 TE/TN) | Cohort 2,Group 6: LDV/SOF+RBV 12 wk (GT3 TE) | Cohort 3,Group 1: LDV/SOF 12 wk (GT1 Cirrhotic CPT B) | Cohort 4,Group 1: SOF+VEL 25mg 8 wk (GT3 TN Noncirrhotic) | Cohort 4,Group 2: SOF+VEL 25mg+RBV 8 wk (GT3 TN Noncirrhotic) | Cohort 4,Group 3: SOF+VEL 100mg 8 wk (GT3 TN Noncirrhotic) | Cohort 4,Group 4: SOF+VEL 100mg+RBV 8 wk (GT3 TN Noncirrhotic) | Cohort 5,Group 1: LDV/SOF+RBV 24 wk (GT1/3 SOF Retreatment) | Cohort 6,Group 1: LDV/SOF 12 wk (GT1, HCV and HBV Coinfection) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Percentage of Participants With Adverse Events Leading to Permanent Discontinuation of Study Drug(s) | 0 | 0 | 4.0 | 0 | 4.0 | 0 | 0 | 2.0 | 0 | 0 | 4.2 | 0 | 3.8 | 5.0 | 0 |
| percentage of participants | Cohort 1,Group 1: LDV/SOF+RBV 12 wk (GT1 SOF Retreatment) | Cohort 1,Group 2: SOF+Peg+RBV 12 wk (GT2,3 SOF Retreatment) | Cohort 2,Group 1: LDV/SOF+RBV 12 wk (GT 1 TE, Liver Disease) | Cohort 2,Group 2: LDV/SOF+GS-9669 12 wk (GT1 TE, Liver Disease | Cohort 2,Group 3: LDV/SOF 12 wk (GT3 TN) | Cohort 2,Group 4: LDV/SOF+RBV 12 wk (GT3 TN) | Cohort 2,Group 5: LDV/SOF 12 wk (GT6 TE/TN) | Cohort 2,Group 6: LDV/SOF+RBV 12 wk (GT3 TE) | Cohort 3,Group 1: LDV/SOF 12 wk (GT1 Cirrhotic CPT B) | Cohort 4,Group 1: SOF+VEL 25mg 8 wk (GT3 TN Noncirrhotic) | Cohort 4,Group 2: SOF+VEL 25mg+RBV 8 wk (GT3 TN Noncirrhotic) | Cohort 4,Group 3: SOF+VEL 100mg 8 wk (GT3 TN Noncirrhotic) | Cohort 4,Group 4: SOF+VEL 100mg+RBV 8 wk (GT3 TN Noncirrhotic) | Cohort 5,Group 1: LDV/SOF+RBV 24 wk (GT1/3 SOF Retreatment) | Cohort 6,Group 1: LDV/SOF 12 wk (GT1, HCV and HBV Coinfection) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 1 | 15.8 | 30.0 | 4.0 | 11.5 | 20.0 | 11.5 | 12.0 | 12.0 | 0 | 33.3 | 4.2 | 26.9 | 19.2 | 15.0 | 12.5 |
| Week 2 | 63.2 | 50.0 | 44.0 | 53.8 | 64.0 | 61.5 | 56.0 | 52.0 | 25.0 | 70.4 | 66.7 | 65.4 | 69.2 | 45.0 | 75.0 |
| percentage of participants | Cohort 1,Group 1: LDV/SOF+RBV 12 wk (GT1 SOF Retreatment) | Cohort 1,Group 2: SOF+Peg+RBV 12 wk (GT2,3 SOF Retreatment) | Cohort 2,Group 1: LDV/SOF+RBV 12 wk (GT 1 TE, Liver Disease) | Cohort 2,Group 2: LDV/SOF+GS-9669 12 wk (GT1 TE, Liver Disease | Cohort 2,Group 3: LDV/SOF 12 wk (GT3 TN) | Cohort 2,Group 4: LDV/SOF+RBV 12 wk (GT3 TN) | Cohort 2,Group 5: LDV/SOF 12 wk (GT6 TE/TN) | Cohort 2,Group 6: LDV/SOF+RBV 12 wk (GT3 TE) | Cohort 3,Group 1: LDV/SOF 12 wk (GT1 Cirrhotic CPT B) | Cohort 4,Group 1: SOF+VEL 25mg 8 wk (GT3 TN Noncirrhotic) | Cohort 4,Group 2: SOF+VEL 25mg+RBV 8 wk (GT3 TN Noncirrhotic) | Cohort 4,Group 3: SOF+VEL 100mg 8 wk (GT3 TN Noncirrhotic) | Cohort 4,Group 4: SOF+VEL 100mg+RBV 8 wk (GT3 TN Noncirrhotic) | Cohort 5,Group 1: LDV/SOF+RBV 24 wk (GT1/3 SOF Retreatment) | Cohort 6,Group 1: LDV/SOF 12 wk (GT1, HCV and HBV Coinfection) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 4 | 100.0 | 100.0 | 84.0 | 92.3 | 95.8 | 88.5 | 96.0 | 96.0 | 75.0 | 96.3 | 95.7 | 92.3 | 96.2 | 75.0 | 87.5 |
| Week 6 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 96.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 90.0 | 100.0 |
| Week 8 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 90.0 | 100.0 |
| percentage of participants | Cohort 1,Group 1: LDV/SOF+RBV 12 wk (GT1 SOF Retreatment) | Cohort 1,Group 2: SOF+Peg+RBV 12 wk (GT2,3 SOF Retreatment) | Cohort 2,Group 1: LDV/SOF+RBV 12 wk (GT 1 TE, Liver Disease) | Cohort 2,Group 2: LDV/SOF+GS-9669 12 wk (GT1 TE, Liver Disease | Cohort 2,Group 3: LDV/SOF 12 wk (GT3 TN) | Cohort 2,Group 4: LDV/SOF+RBV 12 wk (GT3 TN) | Cohort 2,Group 5: LDV/SOF 12 wk (GT6 TE/TN) | Cohort 2,Group 6: LDV/SOF+RBV 12 wk (GT3 TE) | Cohort 3,Group 1: LDV/SOF 12 wk (GT1 Cirrhotic CPT B) | Cohort 5,Group 1: LDV/SOF+RBV 24 wk (GT1/3 SOF Retreatment) | Cohort 6,Group 1: LDV/SOF 12 wk (GT1, HCV and HBV Coinfection) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Percentage of Participants With HCV RNA < LLOQ (15 IU/mL) While on Treatment | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 98.0 | 100.0 | 100.0 | 100.0 |
| percentage of participants | Cohort 1,Group 1: LDV/SOF+RBV 12 wk (GT1 SOF Retreatment) | Cohort 1,Group 2: SOF+Peg+RBV 12 wk (GT2,3 SOF Retreatment) | Cohort 2,Group 1: LDV/SOF+RBV 12 wk (GT 1 TE, Liver Disease) | Cohort 2,Group 2: LDV/SOF+GS-9669 12 wk (GT1 TE, Liver Disease | Cohort 2,Group 3: LDV/SOF 12 wk (GT3 TN) | Cohort 2,Group 4: LDV/SOF+RBV 12 wk (GT3 TN) | Cohort 2,Group 5: LDV/SOF 12 wk (GT6 TE/TN) | Cohort 2,Group 6: LDV/SOF+RBV 12 wk (GT3 TE) | Cohort 3,Group 1: LDV/SOF 12 wk (GT1 Cirrhotic CPT B) | Cohort 5,Group 1: LDV/SOF+RBV 24 wk (GT1/3 SOF Retreatment) | Cohort 6,Group 1: LDV/SOF 12 wk (GT1, HCV and HBV Coinfection) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Percentage of Participants With HCV RNA < LLOQ (15 IU/mL) While on Treatment | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 98.0 | 100.0 | 100.0 | 100.0 |
| percentage of participants | Cohort 5,Group 1: LDV/SOF+RBV 24 wk (GT1/3 SOF Retreatment) |
|---|---|
| Week 16 | 100.0 |
| Week 20 | 100.0 |
| Week 24 | 100.0 |
| percentage of participants | Cohort 1,Group 1: LDV/SOF+RBV 12 wk (GT1 SOF Retreatment) | Cohort 1,Group 2: SOF+Peg+RBV 12 wk (GT2,3 SOF Retreatment) | Cohort 2,Group 1: LDV/SOF+RBV 12 wk (GT 1 TE, Liver Disease) | Cohort 2,Group 2: LDV/SOF+GS-9669 12 wk (GT1 TE, Liver Disease | Cohort 2,Group 3: LDV/SOF 12 wk (GT3 TN) | Cohort 2,Group 4: LDV/SOF+RBV 12 wk (GT3 TN) | Cohort 2,Group 5: LDV/SOF 12 wk (GT6 TE/TN) | Cohort 2,Group 6: LDV/SOF+RBV 12 wk (GT3 TE) | Cohort 3,Group 1: LDV/SOF 12 wk (GT1 Cirrhotic CPT B) | Cohort 4,Group 1: SOF+VEL 25mg 8 wk (GT3 TN Noncirrhotic) | Cohort 4,Group 2: SOF+VEL 25mg+RBV 8 wk (GT3 TN Noncirrhotic) | Cohort 4,Group 3: SOF+VEL 100mg 8 wk (GT3 TN Noncirrhotic) | Cohort 4,Group 4: SOF+VEL 100mg+RBV 8 wk (GT3 TN Noncirrhotic) | Cohort 5,Group 1: LDV/SOF+RBV 24 wk (GT1/3 SOF Retreatment) | Cohort 6,Group 1: LDV/SOF 12 wk (GT1, HCV and HBV Coinfection) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SVR2 | 100.0 | 100.0 | 100.0 | 100.0 | 72.0 | 100.0 | 100.0 | 90.0 | 95.0 | 100.0 | 87.5 | 96.3 | 100.0 | 95.0 | 100.0 |
| SVR4 | 100.0 | 100.0 | 84.0 | 92.3 | 95.8 | 88.5 | 96.0 | 96.0 | 75.0 | 96.3 | 95.7 | 92.3 | 96.2 | 75.0 | 87.5 |
| SVR8 | 100.0 | 90.0 | 100.0 | 100.0 | 64.0 | 100.0 | 96.0 | 82.0 | 65.0 | 100.0 | 87.5 | 96.3 | 100.0 | 80.0 | 100.0 |
| SVR24 | 100.0 | 90.0 | 100.0 | 100.0 | 64.0 | 100.0 | 96.0 | 82.0 | 65.0 | 100.0 | 87.5 | 96.3 | 100.0 | 75.0 | 100.0 |
| percentage of participants | Cohort 6,Group 1: LDV/SOF 12 wk (GT1, HCV and HBV Coinfection) |
|---|---|
| SVR16 | 100 |
| SVR20 | 100 |
On-treatment virologic failure was defined as: * Breakthrough (confirmed HCV RNA ≥ LLOQ after having previously had HCV RNA \< LLOQ while on treatment), or * Rebound (confirmed \> 1 log10 IU/mL increase in HCV RNA from nadir while on treatment), or * Non-response (HCV RNA persistently ≥ LLOQ through 8 weeks of treatment)
| percentage of participants | Cohort 1,Group 1: LDV/SOF+RBV 12 wk (GT1 SOF Retreatment) | Cohort 1,Group 2: SOF+Peg+RBV 12 wk (GT2,3 SOF Retreatment) | Cohort 2,Group 1: LDV/SOF+RBV 12 wk (GT 1 TE, Liver Disease) | Cohort 2,Group 2: LDV/SOF+GS-9669 12 wk (GT1 TE, Liver Disease | Cohort 2,Group 3: LDV/SOF 12 wk (GT3 TN) | Cohort 2,Group 4: LDV/SOF+RBV 12 wk (GT3 TN) | Cohort 2,Group 5: LDV/SOF 12 wk (GT6 TE/TN) | Cohort 2,Group 6: LDV/SOF+RBV 12 wk (GT3 TE) | Cohort 3,Group 1: LDV/SOF 12 wk (GT1 Cirrhotic CPT B) | Cohort 4,Group 1: SOF+VEL 25mg 8 wk (GT3 TN Noncirrhotic) | Cohort 4,Group 2: SOF+VEL 25mg+RBV 8 wk (GT3 TN Noncirrhotic) | Cohort 4,Group 3: SOF+VEL 100mg 8 wk (GT3 TN Noncirrhotic) | Cohort 4,Group 4: SOF+VEL 100mg+RBV 8 wk (GT3 TN Noncirrhotic) | Cohort 5,Group 1: LDV/SOF+RBV 24 wk (GT1/3 SOF Retreatment) | Cohort 6,Group 1: LDV/SOF 12 wk (GT1, HCV and HBV Coinfection) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Percentage of Participants With On-treatment Virologic Failure | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Viral relapse is defined as HCV RNA ≥ LLOQ during the post-treatment period having achieved HCV RNA \< LLOQ at end of treatment, confirmed with 2 consecutive values or last available post-treatment measurement.
| percentage of participants | Cohort 1,Group 1: LDV/SOF+RBV 12 wk (GT1 SOF Retreatment) | Cohort 1,Group 2: SOF+Peg+RBV 12 wk (GT2,3 SOF Retreatment) | Cohort 2,Group 1: LDV/SOF+RBV 12 wk (GT 1 TE, Liver Disease) | Cohort 2,Group 2: LDV/SOF+GS-9669 12 wk (GT1 TE, Liver Disease | Cohort 2,Group 3: LDV/SOF 12 wk (GT3 TN) | Cohort 2,Group 4: LDV/SOF+RBV 12 wk (GT3 TN) | Cohort 2,Group 5: LDV/SOF 12 wk (GT6 TE/TN) | Cohort 2,Group 6: LDV/SOF+RBV 12 wk (GT3 TE) | Cohort 3,Group 1: LDV/SOF 12 wk (GT1 Cirrhotic CPT B) | Cohort 4,Group 1: SOF+VEL 25mg 8 wk (GT3 TN Noncirrhotic) | Cohort 4,Group 2: SOF+VEL 25mg+RBV 8 wk (GT3 TN Noncirrhotic) | Cohort 4,Group 3: SOF+VEL 100mg 8 wk (GT3 TN Noncirrhotic) | Cohort 4,Group 4: SOF+VEL 100mg+RBV 8 wk (GT3 TN Noncirrhotic) | Cohort 5,Group 1: LDV/SOF+RBV 24 wk (GT1/3 SOF Retreatment) | Cohort 6,Group 1: LDV/SOF 12 wk (GT1, HCV and HBV Coinfection) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Percentage of Participants Experiencing Viral Relapse | 0 | 10.0 | 0 | 0 | 33.3 | 0 | 4.0 | 16.3 | 35.0 | 0 | 8.7 | 0 | 0 | 15.0 | 0 |
Collected over Up to 24 Weeks plus 30 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1,Group 1: LDV/SOF+RBV 12 wk (GT1 SOF Retreatment) | — | 0/19 (0%) | 17/19 (89.5%) |
| Cohort 1,Group 2: SOF+Peg+RBV 12 wk (GT2,3 SOF Retreatment) | — | 0/10 (0%) | 10/10 (100%) |
| Cohort 2,Group 1: LDV/SOF+RBV 12 wk (GT 1 TE, Liver Disease) | — | 1/25 (4%) | 24/25 (96%) |
| Cohort 2,Group 2: LDV/SOF+GS-9669 12 wk (GT1 TE, Liver Disease | — | 0/26 (0%) | 24/26 (92.3%) |
| Cohort 2,Group 3: LDV/SOF 12 wk (GT3 TN) | — | 4/25 (16%) | 24/25 (96%) |
| Cohort 2,Group 4: LDV/SOF+RBV 12 wk (GT3 TN) | — | 0/26 (0%) | 23/26 (88.5%) |
| Cohort 2,Group 5: LDV/SOF 12 wk (GT6 TE/TN) | — | 1/25 (4%) | 21/25 (84%) |
| Cohort 2,Group 6: LDV/SOF+RBV 12 wk (GT3 TE) | — | 1/50 (2%) | 43/50 (86%) |
| Cohort 3,Group 1: LDV/SOF 12 wk (GT1 Cirrhotic CPT B) | — | 2/20 (10%) | 19/20 (95%) |
| Cohort 5,Group 1: LDV/SOF+RBV 24 wk (GT1/3 SOF Retreatment) | — | 3/20 (15%) | 17/20 (85%) |
| Cohort 6,Group 1: LDV/SOF 12 wk (GT1, HCV and HBV Coinfection) | — | 0/8 (0%) | 6/8 (75%) |
| Cohort 4,Group 1: SOF+VEL 25mg 8 wk (GT3 TN Noncirrhotic) | — | 1/27 (3.7%) | 18/27 (66.7%) |
| Cohort 4,Group 2: SOF+VEL 25mg+RBV 8 wk (GT3 TN Noncirrhotic) | — | 0/24 (0%) | 18/24 (75%) |
| Cohort 4,Group 3: SOF+VEL 100mg 8 wk (GT3 TN Noncirrhotic) | — | 0/27 (0%) | 22/27 (81.5%) |
| Cohort 4,Group 4: SOF+VEL 100mg+RBV 8 wk (GT3 TN Noncirrhotic) | — | 0/26 (0%) | 21/26 (80.8%) |
| Event | Cohort 1,Group 1: LDV/SOF+RBV 12 wk (GT1 SOF Retreatment) | Cohort 1,Group 2: SOF+Peg+RBV 12 wk (GT2,3 SOF Retreatment) | Cohort 2,Group 1: LDV/SOF+RBV 12 wk (GT 1 TE, Liver Disease) | Cohort 2,Group 2: LDV/SOF+GS-9669 12 wk (GT1 TE, Liver Disease | Cohort 2,Group 3: LDV/SOF 12 wk (GT3 TN) | Cohort 2,Group 4: LDV/SOF+RBV 12 wk (GT3 TN) | Cohort 2,Group 5: LDV/SOF 12 wk (GT6 TE/TN) | Cohort 2,Group 6: LDV/SOF+RBV 12 wk (GT3 TE) | Cohort 3,Group 1: LDV/SOF 12 wk (GT1 Cirrhotic CPT B) | Cohort 5,Group 1: LDV/SOF+RBV 24 wk (GT1/3 SOF Retreatment) | Cohort 6,Group 1: LDV/SOF 12 wk (GT1, HCV and HBV Coinfection) | Cohort 4,Group 1: SOF+VEL 25mg 8 wk (GT3 TN Noncirrhotic) | Cohort 4,Group 2: SOF+VEL 25mg+RBV 8 wk (GT3 TN Noncirrhotic) | Cohort 4,Group 3: SOF+VEL 100mg 8 wk (GT3 TN Noncirrhotic) | Cohort 4,Group 4: SOF+VEL 100mg+RBV 8 wk (GT3 TN Noncirrhotic) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hepatic cirrhosisHepatobiliary disorders | 0/19 | 0/10 | 0/25 | 0/26 | 0/25 | 0/26 | 0/25 | 0/50 | 0/20 | 1/20 | 0/8 | 0/27 | 0/24 | 0/27 | 0/26 |
| Lower respiratory tract infectionInfections and infestations | 0/19 | 0/10 | 0/25 | 0/26 | 0/25 | 0/26 | 0/25 | 0/50 | 0/20 | 1/20 | 0/8 | 0/27 | 0/24 | 0/27 | 0/26 |
| Hepatocellular carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/19 | 0/10 | 0/25 | 0/26 | 0/25 | 0/26 | 0/25 | 0/50 | 0/20 | 1/20 | 0/8 | 0/27 | 0/24 | 0/27 | 0/26 |
| Squamous cell carcinoma of the tongueNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/19 | 0/10 | 0/25 | 0/26 | 0/25 | 0/26 | 0/25 | 0/50 | 1/20 | 0/20 | 0/8 | 0/27 | 0/24 | 0/27 | 0/26 |
| EncephalopathyNervous system disorders | 0/19 | 0/10 | 0/25 | 0/26 | 0/25 | 0/26 | 0/25 | 0/50 | 0/20 | 1/20 | 0/8 | 0/27 | 0/24 | 0/27 | 0/26 |
| Acute kidney injuryRenal and urinary disorders | 0/19 | 0/10 | 0/25 | 0/26 | 0/25 | 0/26 | 0/25 | 0/50 | 1/20 | 0/20 | 0/8 | 0/27 | 0/24 | 0/27 | 0/26 |
| Angina pectorisCardiac disorders | 0/19 | 0/10 | 1/25 | 0/26 | 0/25 | 0/26 | 0/25 | 0/50 | 0/20 | 0/20 | 0/8 | 0/27 | 0/24 | 0/27 | 0/26 |
| Pericardial effusionCardiac disorders | 0/19 | 0/10 | 1/25 | 0/26 | 0/25 | 0/26 | 0/25 | 0/50 | 0/20 | 0/20 | 0/8 | 0/27 | 0/24 | 0/27 | 0/26 |
| Choroidal effusionEye disorders | 0/19 | 0/10 | 0/25 | 0/26 | 1/25 | 0/26 | 0/25 | 0/50 | 0/20 | 0/20 | 0/8 | 0/27 | 0/24 | 0/27 | 0/26 |
| Lens dislocationEye disorders | 0/19 | 0/10 | 0/25 | 0/26 | 1/25 | 0/26 | 0/25 | 0/50 | 0/20 | 0/20 | 0/8 | 0/27 | 0/24 | 0/27 | 0/26 |
| Event | Cohort 1,Group 1: LDV/SOF+RBV 12 wk (GT1 SOF Retreatment) | Cohort 1,Group 2: SOF+Peg+RBV 12 wk (GT2,3 SOF Retreatment) | Cohort 2,Group 1: LDV/SOF+RBV 12 wk (GT 1 TE, Liver Disease) | Cohort 2,Group 2: LDV/SOF+GS-9669 12 wk (GT1 TE, Liver Disease | Cohort 2,Group 3: LDV/SOF 12 wk (GT3 TN) | Cohort 2,Group 4: LDV/SOF+RBV 12 wk (GT3 TN) | Cohort 2,Group 5: LDV/SOF 12 wk (GT6 TE/TN) | Cohort 2,Group 6: LDV/SOF+RBV 12 wk (GT3 TE) | Cohort 3,Group 1: LDV/SOF 12 wk (GT1 Cirrhotic CPT B) | Cohort 5,Group 1: LDV/SOF+RBV 24 wk (GT1/3 SOF Retreatment) | Cohort 6,Group 1: LDV/SOF 12 wk (GT1, HCV and HBV Coinfection) | Cohort 4,Group 1: SOF+VEL 25mg 8 wk (GT3 TN Noncirrhotic) | Cohort 4,Group 2: SOF+VEL 25mg+RBV 8 wk (GT3 TN Noncirrhotic) | Cohort 4,Group 3: SOF+VEL 100mg 8 wk (GT3 TN Noncirrhotic) | Cohort 4,Group 4: SOF+VEL 100mg+RBV 8 wk (GT3 TN Noncirrhotic) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Viral infectionInfections and infestations | 0/19 | 0/10 | 4/25 | 0/26 | 0/25 | 0/26 | 2/25 | 1/50 | 0/20 | 1/20 | 5/8 | 0/27 | 0/24 | 1/27 | 0/26 |
| NauseaGastrointestinal disorders | 4/19 | 3/10 | 7/25 | 11/26 | 9/25 | 4/26 | 0/25 | 5/50 | 3/20 | 1/20 | 0/8 | 4/27 | 1/24 | 4/27 | 3/26 |
| Upper respiratory tract infectionInfections and infestations | 4/19 | 1/10 | 8/25 | 5/26 | 9/25 | 9/26 | 6/25 | 9/50 | 8/20 | 6/20 | 2/8 | 1/27 | 3/24 | 3/27 | 4/26 |
| HeadacheNervous system disorders | 5/19 | 2/10 | 10/25 | 9/26 | 10/25 | 8/26 | 2/25 | 13/50 | 4/20 | 3/20 | 0/8 | 6/27 | 5/24 | 3/27 | 4/26 |
| InsomniaPsychiatric disorders | 7/19 | 2/10 | 7/25 | 1/26 | 3/25 | 3/26 | 0/25 | 10/50 | 3/20 | 1/20 | 0/8 | 0/27 | 3/24 | 6/27 | 2/26 |
| FatigueGeneral disorders | 6/19 | 3/10 | 5/25 | 9/26 | 5/25 | 2/26 | 6/25 | 13/50 | 4/20 | 4/20 | 2/8 | 5/27 | 3/24 | 4/27 | 7/26 |
| ChillsGeneral disorders | 0/19 | 3/10 | 0/25 | 0/26 | 0/25 | 0/26 | 0/25 | 0/50 | 0/20 | 0/20 | 0/8 | 0/27 | 0/24 | 0/27 | 0/26 |
| Lower respiratory tract infectionInfections and infestations | 0/19 | 0/10 | 0/25 | 2/26 | 2/25 | 2/26 | 0/25 | 2/50 | 0/20 | 6/20 | 0/8 | 0/27 | 0/24 | 1/27 | 0/26 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 2/19 | 3/10 | 0/25 | 0/26 | 0/25 | 2/26 | 0/25 | 1/50 | 1/20 | 0/20 | 0/8 | 0/27 | 0/24 | 1/27 | 1/26 |
| RashSkin and subcutaneous tissue disorders | 4/19 | 2/10 | 0/25 | 2/26 | 1/25 | 1/26 | 2/25 | 7/50 | 1/20 | 3/20 | 0/8 | 0/27 | 3/24 | 2/27 | 4/26 |
Safety analysis set: Participants who were randomized and received at least 1 dose of study drug.
| Age, Continuous(Years) | Cohort 1,Group 1: LDV/SOF+RBV 12 wk (GT1 SOF Retreatment) | Cohort 1,Group 2: SOF+Peg+RBV 12 wk (GT2,3 SOF Retreatment) | Cohort 2,Group 1: LDV/SOF+RBV 12 wk (GT 1 TE, Liver Disease) | Cohort 2,Group 2: LDV/SOF+GS-9669 12 wk (GT1 TE, Liver Disease | Cohort 2,Group 3: LDV/SOF 12 wk (GT3 TN) | Cohort 2,Group 4: LDV/SOF+RBV 12 wk (GT3 TN) | Cohort 2,Group 5: LDV/SOF 12 wk (GT6 TE/TN) | Cohort 2,Group 6: LDV/SOF+RBV 12 wk (GT3 TE) | Cohort 3,Group 1: LDV/SOF 12 wk (GT1 Cirrhotic CPT B) | Cohort 4,Group 1: SOF+VEL 25mg 8 wk (GT3 TN Noncirrhotic) | Cohort 4,Group 2: SOF+VEL 25mg+RBV 8 wk (GT3 TN Noncirrhotic) | Cohort 4,Group 3: SOF+VEL 100mg 8 wk (GT3 TN Noncirrhotic) | Cohort 4,Group 4: SOF+VEL 100mg+RBV 8 wk (GT3 TN Noncirrhotic) | Cohort 5,Group 1: LDV/SOF+RBV 24 wk (GT1/3 SOF Retreatment) | Cohort 6,Group 1: LDV/SOF 12 wk (GT1, HCV and HBV Coinfection) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 55 ± 6.1 | 49 ± 12.5 | 56 ± 5.3 | 55 ± 6.7 | 43 ± 10.2 | 48 ± 9.2 | 51 ± 13.9 | 52 ± 8.2 | 56 ± 5.5 | 48 ± 7.9 | 47 ± 7.9 | 50 ± 10.2 | 47 ± 10.3 | 54 ± 7.0 | 53 ± 6.9 | 50.7 ± 9.44 |
| Sex: Female, Male(Participants) | Cohort 1,Group 1: LDV/SOF+RBV 12 wk (GT1 SOF Retreatment) | Cohort 1,Group 2: SOF+Peg+RBV 12 wk (GT2,3 SOF Retreatment) | Cohort 2,Group 1: LDV/SOF+RBV 12 wk (GT 1 TE, Liver Disease) | Cohort 2,Group 2: LDV/SOF+GS-9669 12 wk (GT1 TE, Liver Disease | Cohort 2,Group 3: LDV/SOF 12 wk (GT3 TN) | Cohort 2,Group 4: LDV/SOF+RBV 12 wk (GT3 TN) | Cohort 2,Group 5: LDV/SOF 12 wk (GT6 TE/TN) | Cohort 2,Group 6: LDV/SOF+RBV 12 wk (GT3 TE) | Cohort 3,Group 1: LDV/SOF 12 wk (GT1 Cirrhotic CPT B) | Cohort 4,Group 1: SOF+VEL 25mg 8 wk (GT3 TN Noncirrhotic) | Cohort 4,Group 2: SOF+VEL 25mg+RBV 8 wk (GT3 TN Noncirrhotic) | Cohort 4,Group 3: SOF+VEL 100mg 8 wk (GT3 TN Noncirrhotic) | Cohort 4,Group 4: SOF+VEL 100mg+RBV 8 wk (GT3 TN Noncirrhotic) | Cohort 5,Group 1: LDV/SOF+RBV 24 wk (GT1/3 SOF Retreatment) | Cohort 6,Group 1: LDV/SOF 12 wk (GT1, HCV and HBV Coinfection) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 6 | 2 | 10 | 11 | 12 | 15 | 9 | 11 | 3 | 10 | 6 | 10 | 15 | 2 | 2 | 124 |
| Male | 13 | 8 | 15 | 15 | 13 | 11 | 16 | 39 | 17 | 17 | 18 | 17 | 11 | 18 | 6 | 234 |
| Race/Ethnicity, Customized(participants) | Cohort 1,Group 1: LDV/SOF+RBV 12 wk (GT1 SOF Retreatment) | Cohort 1,Group 2: SOF+Peg+RBV 12 wk (GT2,3 SOF Retreatment) | Cohort 2,Group 1: LDV/SOF+RBV 12 wk (GT 1 TE, Liver Disease) | Cohort 2,Group 2: LDV/SOF+GS-9669 12 wk (GT1 TE, Liver Disease | Cohort 2,Group 3: LDV/SOF 12 wk (GT3 TN) | Cohort 2,Group 4: LDV/SOF+RBV 12 wk (GT3 TN) | Cohort 2,Group 5: LDV/SOF 12 wk (GT6 TE/TN) | Cohort 2,Group 6: LDV/SOF+RBV 12 wk (GT3 TE) | Cohort 3,Group 1: LDV/SOF 12 wk (GT1 Cirrhotic CPT B) | Cohort 4,Group 1: SOF+VEL 25mg 8 wk (GT3 TN Noncirrhotic) | Cohort 4,Group 2: SOF+VEL 25mg+RBV 8 wk (GT3 TN Noncirrhotic) | Cohort 4,Group 3: SOF+VEL 100mg 8 wk (GT3 TN Noncirrhotic) | Cohort 4,Group 4: SOF+VEL 100mg+RBV 8 wk (GT3 TN Noncirrhotic) | Cohort 5,Group 1: LDV/SOF+RBV 24 wk (GT1/3 SOF Retreatment) | Cohort 6,Group 1: LDV/SOF 12 wk (GT1, HCV and HBV Coinfection) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| White | 18 | 9 | 22 | 24 | 22 | 23 | 3 | 40 | 17 | 20 | 20 | 20 | 19 | 18 | 3 | 278 |
| Asian | 0 | 0 | 1 | 0 | 1 | 1 | 22 | 3 | 1 | 1 | 0 | 1 | 0 | 0 | 1 | 32 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 2 | 1 | 1 | 1 | 0 | 5 | 2 | 5 | 2 | 3 | 6 | 1 | 4 | 34 |
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| Other | 1 | 0 | 0 | 1 | 1 | 1 | 0 | 2 | 0 | 1 | 2 | 3 | 0 | 1 | 0 | 13 |
| Race/Ethnicity, Customized(participants) | Cohort 1,Group 1: LDV/SOF+RBV 12 wk (GT1 SOF Retreatment) | Cohort 1,Group 2: SOF+Peg+RBV 12 wk (GT2,3 SOF Retreatment) | Cohort 2,Group 1: LDV/SOF+RBV 12 wk (GT 1 TE, Liver Disease) | Cohort 2,Group 2: LDV/SOF+GS-9669 12 wk (GT1 TE, Liver Disease | Cohort 2,Group 3: LDV/SOF 12 wk (GT3 TN) | Cohort 2,Group 4: LDV/SOF+RBV 12 wk (GT3 TN) | Cohort 2,Group 5: LDV/SOF 12 wk (GT6 TE/TN) | Cohort 2,Group 6: LDV/SOF+RBV 12 wk (GT3 TE) | Cohort 3,Group 1: LDV/SOF 12 wk (GT1 Cirrhotic CPT B) | Cohort 4,Group 1: SOF+VEL 25mg 8 wk (GT3 TN Noncirrhotic) | Cohort 4,Group 2: SOF+VEL 25mg+RBV 8 wk (GT3 TN Noncirrhotic) | Cohort 4,Group 3: SOF+VEL 100mg 8 wk (GT3 TN Noncirrhotic) | Cohort 4,Group 4: SOF+VEL 100mg+RBV 8 wk (GT3 TN Noncirrhotic) | Cohort 5,Group 1: LDV/SOF+RBV 24 wk (GT1/3 SOF Retreatment) | Cohort 6,Group 1: LDV/SOF 12 wk (GT1, HCV and HBV Coinfection) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Not Hispanic or Latino | 19 | 10 | 25 | 26 | 25 | 26 | 25 | 50 | 20 | 27 | 24 | 27 | 26 | 20 | 8 | 358 |
| HCV Genotype(participants) | Cohort 1,Group 1: LDV/SOF+RBV 12 wk (GT1 SOF Retreatment) | Cohort 1,Group 2: SOF+Peg+RBV 12 wk (GT2,3 SOF Retreatment) | Cohort 2,Group 1: LDV/SOF+RBV 12 wk (GT 1 TE, Liver Disease) | Cohort 2,Group 2: LDV/SOF+GS-9669 12 wk (GT1 TE, Liver Disease | Cohort 2,Group 3: LDV/SOF 12 wk (GT3 TN) | Cohort 2,Group 4: LDV/SOF+RBV 12 wk (GT3 TN) | Cohort 2,Group 5: LDV/SOF 12 wk (GT6 TE/TN) | Cohort 2,Group 6: LDV/SOF+RBV 12 wk (GT3 TE) | Cohort 3,Group 1: LDV/SOF 12 wk (GT1 Cirrhotic CPT B) | Cohort 4,Group 1: SOF+VEL 25mg 8 wk (GT3 TN Noncirrhotic) | Cohort 4,Group 2: SOF+VEL 25mg+RBV 8 wk (GT3 TN Noncirrhotic) | Cohort 4,Group 3: SOF+VEL 100mg 8 wk (GT3 TN Noncirrhotic) | Cohort 4,Group 4: SOF+VEL 100mg+RBV 8 wk (GT3 TN Noncirrhotic) | Cohort 5,Group 1: LDV/SOF+RBV 24 wk (GT1/3 SOF Retreatment) | Cohort 6,Group 1: LDV/SOF 12 wk (GT1, HCV and HBV Coinfection) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1b with possible mixed infection with Genotype 4 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Genotype 1a | 16 | 0 | 15 | 22 | 0 | 0 | 0 | 0 | 18 | 0 | 0 | 0 | 0 | 9 | 6 | 86 |
| Genotype 1a with possible 6 (subtypes c - l) | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Genotype 1b | 2 | 0 | 9 | 4 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 2 | 19 |
| Genotype 3 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 3 | 0 | 2 | 1 | 0 | 0 | 0 | 0 | 7 |
| Genotype 3a | 0 | 10 | 0 | 0 | 24 | 25 | 0 | 46 | 0 | 25 | 22 | 27 | 26 | 10 | 0 | 215 |
| Genotype 3k | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
| Genotype 6 (subtypes c - l) | 0 | 0 | 0 | 0 | 0 | 0 | 17 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 17 |
| Genotype 6a or 6b | 0 | 0 | 0 | 0 | 0 | 0 | 8 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8 |
| Indeterminate genotype. Sequencing indicates GT3a | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Indeterminate pattern. Sequencing indicates GT3k | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Missing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| Cirrhosis Status(participants) | Cohort 1,Group 1: LDV/SOF+RBV 12 wk (GT1 SOF Retreatment) | Cohort 1,Group 2: SOF+Peg+RBV 12 wk (GT2,3 SOF Retreatment) | Cohort 2,Group 1: LDV/SOF+RBV 12 wk (GT 1 TE, Liver Disease) | Cohort 2,Group 2: LDV/SOF+GS-9669 12 wk (GT1 TE, Liver Disease | Cohort 2,Group 3: LDV/SOF 12 wk (GT3 TN) | Cohort 2,Group 4: LDV/SOF+RBV 12 wk (GT3 TN) | Cohort 2,Group 5: LDV/SOF 12 wk (GT6 TE/TN) | Cohort 2,Group 6: LDV/SOF+RBV 12 wk (GT3 TE) | Cohort 3,Group 1: LDV/SOF 12 wk (GT1 Cirrhotic CPT B) | Cohort 4,Group 1: SOF+VEL 25mg 8 wk (GT3 TN Noncirrhotic) | Cohort 4,Group 2: SOF+VEL 25mg+RBV 8 wk (GT3 TN Noncirrhotic) | Cohort 4,Group 3: SOF+VEL 100mg 8 wk (GT3 TN Noncirrhotic) | Cohort 4,Group 4: SOF+VEL 100mg+RBV 8 wk (GT3 TN Noncirrhotic) | Cohort 5,Group 1: LDV/SOF+RBV 24 wk (GT1/3 SOF Retreatment) | Cohort 6,Group 1: LDV/SOF 12 wk (GT1, HCV and HBV Coinfection) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No | 18 | 9 | 7 | 9 | 21 | 20 | 23 | 28 | 0 | 27 | 24 | 27 | 26 | 6 | 6 | 251 |
| Yes | 1 | 1 | 18 | 17 | 4 | 6 | 2 | 22 | 20 | 0 | 0 | 0 | 0 | 14 | 2 | 107 |
| IL28b Status(participants) | Cohort 1,Group 1: LDV/SOF+RBV 12 wk (GT1 SOF Retreatment) | Cohort 1,Group 2: SOF+Peg+RBV 12 wk (GT2,3 SOF Retreatment) | Cohort 2,Group 1: LDV/SOF+RBV 12 wk (GT 1 TE, Liver Disease) | Cohort 2,Group 2: LDV/SOF+GS-9669 12 wk (GT1 TE, Liver Disease | Cohort 2,Group 3: LDV/SOF 12 wk (GT3 TN) | Cohort 2,Group 4: LDV/SOF+RBV 12 wk (GT3 TN) | Cohort 2,Group 5: LDV/SOF 12 wk (GT6 TE/TN) | Cohort 2,Group 6: LDV/SOF+RBV 12 wk (GT3 TE) | Cohort 3,Group 1: LDV/SOF 12 wk (GT1 Cirrhotic CPT B) | Cohort 4,Group 1: SOF+VEL 25mg 8 wk (GT3 TN Noncirrhotic) | Cohort 4,Group 2: SOF+VEL 25mg+RBV 8 wk (GT3 TN Noncirrhotic) | Cohort 4,Group 3: SOF+VEL 100mg 8 wk (GT3 TN Noncirrhotic) | Cohort 4,Group 4: SOF+VEL 100mg+RBV 8 wk (GT3 TN Noncirrhotic) | Cohort 5,Group 1: LDV/SOF+RBV 24 wk (GT1/3 SOF Retreatment) | Cohort 6,Group 1: LDV/SOF 12 wk (GT1, HCV and HBV Coinfection) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CC | 4 | 3 | 6 | 4 | 9 | 15 | 20 | 18 | 7 | 10 | 6 | 15 | 14 | 7 | 7 | 145 |
| CT | 12 | 5 | 12 | 19 | 10 | 6 | 5 | 27 | 6 | 13 | 15 | 11 | 10 | 7 | 1 | 159 |
| TT | 3 | 2 | 7 | 3 | 6 | 5 | 0 | 5 | 7 | 4 | 3 | 1 | 2 | 6 | 0 | 54 |
| HCV RNA(log 10 IU/mL) | Cohort 1,Group 1: LDV/SOF+RBV 12 wk (GT1 SOF Retreatment) | Cohort 1,Group 2: SOF+Peg+RBV 12 wk (GT2,3 SOF Retreatment) | Cohort 2,Group 1: LDV/SOF+RBV 12 wk (GT 1 TE, Liver Disease) | Cohort 2,Group 2: LDV/SOF+GS-9669 12 wk (GT1 TE, Liver Disease | Cohort 2,Group 3: LDV/SOF 12 wk (GT3 TN) | Cohort 2,Group 4: LDV/SOF+RBV 12 wk (GT3 TN) | Cohort 2,Group 5: LDV/SOF 12 wk (GT6 TE/TN) | Cohort 2,Group 6: LDV/SOF+RBV 12 wk (GT3 TE) | Cohort 3,Group 1: LDV/SOF 12 wk (GT1 Cirrhotic CPT B) | Cohort 4,Group 1: SOF+VEL 25mg 8 wk (GT3 TN Noncirrhotic) | Cohort 4,Group 2: SOF+VEL 25mg+RBV 8 wk (GT3 TN Noncirrhotic) | Cohort 4,Group 3: SOF+VEL 100mg 8 wk (GT3 TN Noncirrhotic) | Cohort 4,Group 4: SOF+VEL 100mg+RBV 8 wk (GT3 TN Noncirrhotic) | Cohort 5,Group 1: LDV/SOF+RBV 24 wk (GT1/3 SOF Retreatment) | Cohort 6,Group 1: LDV/SOF 12 wk (GT1, HCV and HBV Coinfection) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Median | 6.3 ± 0.51 | 6.5 ± 0.63 | 6.5 ± 0.39 | 6.1 ± 0.69 | 6.3 ± 0.88 | 6.3 ± 0.87 | 6.7 ± 0.67 | 6.3 ± 0.76 | 6.0 ± 0.48 | 5.9 ± 0.86 | 6.3 ± 0.69 | 6.0 ± 0.71 | 6.2 ± 0.92 | 6.0 ± 0.48 | 6.0 ± 10.9 | 6.2 ± 0.76 |
1 further baseline measures are reported on the registry.
Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at http://www.gilead.com/research/disclosure-and-transparency.
Supporting information: Study protocol, Statistical analysis plan
Time frame: 18 months after study completion
Access criteria: A secured external environment with username, password, and RSA code.
Data sharing details ↗ · www.gilead.com
The record gives a start of Apr 2013, a primary completion of Mar 2015 and a completion of May 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2016, 1 year 6 months after primary completion. A results delay was requested in Jan 2016.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Sofosbuvir · Ribavirin · Interferons · GS-9669 · Velpatasvir